Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS／Cervarix Wins Tender for UK National Immunization Program: GSK
August 4, 2008
- Alizyme Licenses COLAL-PRED to Norgine in Europe
August 4, 2008
- BMS, AZ Apply for Saxagliptin in Europe
August 4, 2008
- BUSINESS NEWS IN BRIEF
August 4, 2008
- Primovist Approved in the US: Bayer HealthCare
August 4, 2008
- TOPICS／JADEC, sanofi-aventis Cosponsor HbA1c Awareness Enhancement Campaign
August 4, 2008
- PMDA Receives Highest Rating Regarding Balance of Payment, Relief of ADR Victims
August 4, 2008
- NEW PRODUCTS／Aroglycem Cap. for Hypoglycemia due to Hyperinsulinemia: Schering-Plough
August 4, 2008
- OPINION／Who Makes \30 Million? Our Survey Reveals All
August 4, 2008
- Irinotecan to See First Generics in November
August 4, 2008
- Kobayashi Launches 7 New Products
August 4, 2008
- Councils for Promotion of Use of Generics Created by 30 Prefectures
August 4, 2008
- Paltac KS to Report Profits This Fiscal Year
August 4, 2008
- More Doctors Concerned about Quality of Generics Based on Their Own Experience
August 4, 2008
- Miconazole, Emedastine Fumarate Classified into Class 1 OTC Drugs
August 4, 2008
- GENERICS NEWS IN BRIEF
August 4, 2008
- Updating Reduces Number of Class 1 OTC Drugs from 23 to 21
August 4, 2008
- Fuji Yakuhin Developing Drug for Gout at PII
August 4, 2008
- SELF-MEDICATION NEWS IN BRIEF
August 4, 2008
- Novartis to Apply for Everolimus for RCC within 2008
August 4, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…